Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Favipiravir granular preparation and preparation method therefor

A technology of lavir granules and granule preparations, which is applied in the field of medicine and can solve the problems of difficult swallowing of tablets and the like

Active Publication Date: 2020-07-28
AC PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Purpose of the invention: In order to solve the technical problems existing in the prior art, the present invention provides a favipiravir granule preparation and a preparation method thereof, which solves the problem that tablets on the market are difficult to swallow, and the prepared granule preparation is convenient for children and elderly patients to take. Good suspension effect, good taste, fast dissolution, simple preparation process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Favipiravir granular preparation and preparation method therefor
  • Favipiravir granular preparation and preparation method therefor
  • Favipiravir granular preparation and preparation method therefor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～4

[0057] The used prescription and prescription consumption of embodiment 1-4 are as shown in table 1 below:

[0058] Table 1

[0059] Component classification name Example 1 Example 2 Example 3 Example 4 parts by weight parts by weight parts by weight parts by weight Main drug Favipiravir 200 200 200 200 filler dextrin 0 200 500 100 suspending agent Tragacanth Gum 10 50 100 150 sweetener sucrose 2000 1300 800 0 sweetener aspartame 0 20 40 80 pH regulator citric acid 1 50 70 120 pH regulator Sodium citrate 10 75 30 20 Glidant Micropowder silica gel 50 50 50 20 Batch / gram 300 300 300 300 Main drug particle size / micron 9.4 38 29 12 Granule formulation pH 5.8 4.9 3.5 2.3 Sedimentation volume ratio 0.91 0.94 0.95 0.96 Taste score 3.1 points 3.7 points 4.3 points 3.5 points

[0060] From the above resu...

Embodiment 1

[0061] Embodiment 1 preparation process steps:

[0062] 1) Favipiravir is subjected to airflow pulverization, the materials are collected, the particle size distribution is measured and controlled, and the D90 is obtained as a bulk drug of 9.4 microns;

[0063] 2) Pass tragacanth gum, sucrose, and micropowdered silica gel through a 60-mesh sieve respectively, and set aside;

[0064] 3) Mix the materials of step 1) and step 2) together in a mixer for 20 minutes to obtain the favipiravir granule formulation.

Embodiment 2～4

[0065] Embodiment 2~4 preparation process steps:

[0066] 1) Favipiravir is subjected to airflow pulverization, the material is collected, and the particle size distribution D90 is measured and controlled to be less than 40 microns;

[0067] 2) Pass the components other than the bulk drug through a 40-mesh sieve respectively, and set aside;

[0068] 3) Mix the other materials except micropowder silica gel and aspartame in step 1) and step 2) in a high-shear granulator, and then add the solution prepared by aspartame and purified water and continue stirring. Get the soft material with suitable wetting degree;

[0069] 4) the soft material of step 3) is carried out wet granulation by using a swing granulator with 40 meshes;

[0070] 5) The material obtained in step 4) is dried, and the obtained dried granules are dry granulated using a 40-mesh screen with an aperture;

[0071] 6) Mix the glidant and the granules obtained in step 5 in a mixer for 10 minutes to obtain the favip...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a Favipiravir granular preparation. The Favipiravir granular preparation contains the following ingredients in parts by weight: 200 parts of Favipiravir, 0-1,000 parts of filler, 10-200 parts of suspending agent, 0.1-2,000 parts of flavoring agent, 0-100 parts of flow aid and a proper amount of pH regulator, wherein the particle size distribution of the Favipiravir meets that D90 is smaller than 40 microns; and a pH value of the granular preparation is controlled to 2.0 to 6.0 through the pH regulator. According to the Favipiravir granular preparation, through controlling particle sizes of bulk drugs and dosage of the suspending agent, after the Favipiravir granular preparation is mixed with water, homogeneous dispersion of a principal drug during clinical use can be effectively guaranteed, and the preparation, which is easy to swallow and flexibly-adjustable in dosage, is provided for clinical work; and further, through controlling a pH range of a suspension prepared from the granular preparation, the influence caused by displeased taste of the drug is reduced. According to the Favipiravir granular preparation, the problem that Favipiravir tablets for saleare difficult in swallowing is solved, the granular preparation is conveniently taken by children and the elderly, the suspending effect is good, the mouth feel is relatively good, the dissolving speed is high, and the preparation process is simple.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a favipiravir granule preparation and a preparation method thereof. Background technique [0002] Favipiravir (favipiravir), the chemical name is 6-fluoro-3-hydroxypyrazine-2-carboxamide, a new broad-spectrum anti-inflammatory drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan Toyama Chemical Pharmaceutical Co., Ltd. Viral drugs, approved for marketing in Japan in March 2014, are used to treat new and recurrent influenza. During the outbreak of the novel coronavirus, the results of the phase I clinical study of the drug released in March 2020 showed that the drug may slow the progression of the novel coronavirus pneumonia by accelerating virus clearance. [0003] The dosage form of favipiravir currently on the market is tablet, administered twice on the first day, 1600 mg each time; on the second to fifth day, twice a day, 600 mg each time. The dosage is v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K47/36A61K31/4965A61P11/00A61P31/14A61P31/16
CPCA61K9/1652A61K9/1682A61K31/4965A61P11/00A61P31/14A61P31/16
Inventor 刘锋谭晓峰梁文伟周伟杰
Owner AC PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com